How have PAVMZ shares performed in 2024?

PAVmed's stock was trading at $0.11 at the beginning of the year. Since then, PAVMZ stock has decreased by 62.6% and is now trading at $0.0411. View the best growth stocks for 2024 here .

Are investors shorting PAVmed?

PAVmed saw a increase in short interest in March. As of March 31st, there was short interest totaling 15,300 shares, an increase of 109.6% from the March 15th total of 7,300 shares. Based on an average trading volume of 9,300 shares, the days-to-cover ratio is presently 1.6 days. View PAVmed's Short Interest .

How do I buy shares of PAVmed?

Shares of PAVMZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PAVMZ

PAVmed (PAVMZ) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free PAVMZ Stock Alerts

$0.04

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.04
▼
$0.04
50-Day Range: $0.02
▼
$0.05
52-Week Range: $0.00
▼
$0.27

Volume: N/A
Average Volume: 11,133 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Ownership SEC Filings Short Interest Social Media

Get PAVmed alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About PAVmed Stock (NASDAQ:PAVMZ)

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

PAVMZ Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PAVMZ Stock News Headlines

March 27, 2024 | investorplace.com

PAVM Stock Earnings: PAVmed Beats EPS, Misses Revenue for Q4 2023

See More Headlines

Receive PAVMZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medical Devices
Sub-Industry: N/A
Current Symbol: NASDAQ:PAVMZ
CUSIP: N/A
CIK: 1624326
Web: www.pavm.com
Phone: 12129494319
Fax: N/A
Employees: 124
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $2.45 million
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Lishan Aklog M.D. (Age 58)
Chairman & CEO
Comp: $945.09k
Mr. Shaun M. O'Neill M.B.A. (Age 41)
Executive VP & COO
Comp: $447.47k
Dr. Brian J. deGuzman M.D. (Age 59)
Executive VP, Chief Technology & Compliance Officer
Comp: $427.6k
Dr. Suman M. Verma M.D.
Ph.D., Senior VP of Molecular Genetics & Chief Scientific Officer
Michael Parks
Vice President of Investor Relations
Mr. Michael Adam Gordon (Age 50)
Executive VP, General Counsel & Secretary
Dr. Deepika A. Lakhani Ph.D.
Senior VP, Chief Regulatory & Quality Officer
Dr. Victoria T. Lee M.D.
Senior VP & Chief Medical Officer

Key Competitors

View All Competitors

PAVMZ Stock Analysis - Frequently Asked Questions

How have PAVMZ shares performed in 2024?: PAVmed's stock was trading at $0.11 at the beginning of the year. Since then, PAVMZ stock has decreased by 62.6% and is now trading at $0.0411.
View the best growth stocks for 2024 here.
Are investors shorting PAVmed?: PAVmed saw a increase in short interest in March. As of March 31st, there was short interest totaling 15,300 shares, an increase of 109.6% from the March 15th total of 7,300 shares. Based on an average trading volume of 9,300 shares, the days-to-cover ratio is presently 1.6 days.
View PAVmed's Short Interest.
How do I buy shares of PAVmed?: Shares of PAVMZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PAVMZ) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial